An Investigation of the Biological and Neuronal Mechanisms of Post Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury
| Status: | Recruiting |
|---|---|
| Conditions: | Depression, Depression, Hospital, Neurology, Psychiatric, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 11/7/2018 |
| Start Date: | December 20, 2013 |
| End Date: | July 1, 2019 |
| Contact: | Mary V Ley, R.N. |
| Email: | mley@mail.nih.gov |
| Phone: | (301) 496-3950 |
An Investigation of the Biological and Neuronal Mechanisms of Post-Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury
Background: A traumatic brain injury (TBI) could mean a person is at high risk for other
long-lasting problems. These problems could include post-traumatic stress disorder (PTSD),
depression, and post-concussive syndrome (PCS). For example, about 700,000 Americans each
year who have a TBI later go on to have PTSD also. Depression and PCS are also common in
people who had a TBI. Some people will have these problems later. These problems can
seriously interfere with a person s life. Some people will not have these problems at all.
There are many reasons for this difference. Researchers think the main reason is that people
have different genetic and environmental influences. Right now, we only have few kinds of
treatments to prevent or treat these problems after a TBI. The few treatments we have often
do not work well. It is important to understand what factors make a person at high risk for
these problems after a TBI. This could allow researchers and doctors to help address these
problems early. Addressing these problems earlier may help a person have better health in the
long run.
Objectives:
To study the biological changes that happen after mild to moderate TBI which could be linked
to the onset of PTSD, depression, and post-concussive syndrome
To study brain mechanisms that could explain risks for getting a psychiatric disorder after
mild to moderate TBI. This will be done using a test called functional MRI (fMRI). This test
takes images of the brain while a person is doing a simple task.
Eligibility:
Men and women who are 18 to 65 years old.
Had a mild to moderate TBI (including concussion) in the last month.
Design:
5 outpatient visits to the NIH Clinical Center over one year.
The first visit is a screening visit to see if you can join the study. This visit must happen
within 30 days of the TBI. The visit includes lab work (blood and urine), a history and
physical exam done by a physician or nurse practitioner, and a psychiatric interview with a
behavioral health nurse.
Visits 2, 3, 4 and 5 happen at one, three, six and twelve months post-injury. At these visits
participants may have some or all of the following tests: blood and saliva collection, urine
collection, questionnaires and interviews to assess symptoms, a test to see your response to
stress (called hydrocortisone challenge), and fMRI brain imaging.
This study does not provide treatment.
This study is not a substitute for seeing a primary care provider.
This study should not replace any therapies you may be taking.
long-lasting problems. These problems could include post-traumatic stress disorder (PTSD),
depression, and post-concussive syndrome (PCS). For example, about 700,000 Americans each
year who have a TBI later go on to have PTSD also. Depression and PCS are also common in
people who had a TBI. Some people will have these problems later. These problems can
seriously interfere with a person s life. Some people will not have these problems at all.
There are many reasons for this difference. Researchers think the main reason is that people
have different genetic and environmental influences. Right now, we only have few kinds of
treatments to prevent or treat these problems after a TBI. The few treatments we have often
do not work well. It is important to understand what factors make a person at high risk for
these problems after a TBI. This could allow researchers and doctors to help address these
problems early. Addressing these problems earlier may help a person have better health in the
long run.
Objectives:
To study the biological changes that happen after mild to moderate TBI which could be linked
to the onset of PTSD, depression, and post-concussive syndrome
To study brain mechanisms that could explain risks for getting a psychiatric disorder after
mild to moderate TBI. This will be done using a test called functional MRI (fMRI). This test
takes images of the brain while a person is doing a simple task.
Eligibility:
Men and women who are 18 to 65 years old.
Had a mild to moderate TBI (including concussion) in the last month.
Design:
5 outpatient visits to the NIH Clinical Center over one year.
The first visit is a screening visit to see if you can join the study. This visit must happen
within 30 days of the TBI. The visit includes lab work (blood and urine), a history and
physical exam done by a physician or nurse practitioner, and a psychiatric interview with a
behavioral health nurse.
Visits 2, 3, 4 and 5 happen at one, three, six and twelve months post-injury. At these visits
participants may have some or all of the following tests: blood and saliva collection, urine
collection, questionnaires and interviews to assess symptoms, a test to see your response to
stress (called hydrocortisone challenge), and fMRI brain imaging.
This study does not provide treatment.
This study is not a substitute for seeing a primary care provider.
This study should not replace any therapies you may be taking.
Objective: A traumatic brain injury (TBI) places individuals at high risk for developing
posttraumatic stress disorder (PTSD). TBIs account for the onset of PTSD in approximately
700,000 Americans each year. Depression and post-concussive syndrome (PCS) are also common
and often comorbid with PTSD. However, even in this group, there is a high-level of
inter-individual response to traumatic brain injuries, suggesting that a better understanding
of the mechanisms underlying this risk would be of great value in directing preventive
interventions. The reasons for this heterogeneity are undoubtedly multi-factorial, and
involve a complex interplay between genetic and environmental factors, that we may be able to
understand through peripheral biomarkers and central examination of neuronal functioning. We
suggest that DNA methylation may be a putative biomarker of psychiatric risk, as it reflects
long-term changes in the function of the gene and may shape the recovery ability of the TBI
patient through changes in cell function. In addition, differential proteomic response,
including the function of the neuroendocrine system, likely relates to changes from
epigenetic modification in both neurons and immune cells, which may contribute to the risk
for the onset of PTSD as well as depression and PCS. We have previously shown that both PTSD
and depression are associated with endocrine alterations, leading us to question if this
biological change may underlie vulnerability for the onset of PTSD as well as depression and
PCS following a TBI. In support of the idea of shared vulnerability, patients with a TBI also
often display endocrine function alterations. In addition, sleep disturbance is common
following TBI and is a core symptom of PTSD depression and PCS, suggesting that sleep may
contribute to psychiatric and neurological recovery from a TBI. This line of research is
essential, as current treatments to prevent or treat psychiatric risk following TBI are often
ineffective, and even treatment of PCS is limited. This poor understanding results in our
limited ability to reduce the risk for compromises in the health and well-being of patients
who sustain a TBI.
Study population: Participants with a moderate or mild TBI (n=100) will be followed for a
period of one year.
Design: This is a natural history study that will recruit patients within 30 days of a
mild/moderate TBI, and will follow them over a one year period, with follow-up at 1, 3, 6 and
12 months following the TBI. Biological profiles including the concentration of inflammatory
proteins and neuropeptides, and DNA methylation will be examined. An optional structural and
functional magnetic resonance imaging (fMRI), and a hydrocortisone stimulation test will be
used to evaluate the role of neuronal and neuroendocrine functioning following TBI.
Outcome measures: The primary outcomes of interest are the biological changes that occur
following TBI which are associated with the onset of psychiatric disorders of PTSD, and
depression, as well as the onset of PCS. The secondary aim is to examine neuronal mechanisms
that underlie the risks for these disorders through the use of fMRI. Additional aims will
determine the role of psychological resilience traits in recovery and also how sleep relates
to recovery and psychiatric risk.
posttraumatic stress disorder (PTSD). TBIs account for the onset of PTSD in approximately
700,000 Americans each year. Depression and post-concussive syndrome (PCS) are also common
and often comorbid with PTSD. However, even in this group, there is a high-level of
inter-individual response to traumatic brain injuries, suggesting that a better understanding
of the mechanisms underlying this risk would be of great value in directing preventive
interventions. The reasons for this heterogeneity are undoubtedly multi-factorial, and
involve a complex interplay between genetic and environmental factors, that we may be able to
understand through peripheral biomarkers and central examination of neuronal functioning. We
suggest that DNA methylation may be a putative biomarker of psychiatric risk, as it reflects
long-term changes in the function of the gene and may shape the recovery ability of the TBI
patient through changes in cell function. In addition, differential proteomic response,
including the function of the neuroendocrine system, likely relates to changes from
epigenetic modification in both neurons and immune cells, which may contribute to the risk
for the onset of PTSD as well as depression and PCS. We have previously shown that both PTSD
and depression are associated with endocrine alterations, leading us to question if this
biological change may underlie vulnerability for the onset of PTSD as well as depression and
PCS following a TBI. In support of the idea of shared vulnerability, patients with a TBI also
often display endocrine function alterations. In addition, sleep disturbance is common
following TBI and is a core symptom of PTSD depression and PCS, suggesting that sleep may
contribute to psychiatric and neurological recovery from a TBI. This line of research is
essential, as current treatments to prevent or treat psychiatric risk following TBI are often
ineffective, and even treatment of PCS is limited. This poor understanding results in our
limited ability to reduce the risk for compromises in the health and well-being of patients
who sustain a TBI.
Study population: Participants with a moderate or mild TBI (n=100) will be followed for a
period of one year.
Design: This is a natural history study that will recruit patients within 30 days of a
mild/moderate TBI, and will follow them over a one year period, with follow-up at 1, 3, 6 and
12 months following the TBI. Biological profiles including the concentration of inflammatory
proteins and neuropeptides, and DNA methylation will be examined. An optional structural and
functional magnetic resonance imaging (fMRI), and a hydrocortisone stimulation test will be
used to evaluate the role of neuronal and neuroendocrine functioning following TBI.
Outcome measures: The primary outcomes of interest are the biological changes that occur
following TBI which are associated with the onset of psychiatric disorders of PTSD, and
depression, as well as the onset of PCS. The secondary aim is to examine neuronal mechanisms
that underlie the risks for these disorders through the use of fMRI. Additional aims will
determine the role of psychological resilience traits in recovery and also how sleep relates
to recovery and psychiatric risk.
- INCLUSION CRITERIA:
- Participants must be enrolled in CNRM recruiting protocol (11-N-0084) or evaluated for
a TBI at theGeorge Washington University Hospital.
- Participants may be NIH employees/staff, except for those who are employed by NINR or
subordinates, relatives, and/or co-workers of NINR employees/staff or study
investigators.
- Participants will have had a mild to moderate TBI (GCS between 9 and 15) in the
previous 30 days.
- Participants will be between the age of 18 and 65 years
- Ability to give own consent
- Demonstrate understanding of the protocol by passing a short consent quiz with a score
of 6.
EXCLUSION CRITERIA:
- Psychiatric Risks: Actively suicidal or at risk for suicide
- Previous or current diagnosis of schizophrenia, bipolar disorder, other psychoses.
- Current diagnosis of depression.
- Previous or current PTSD.
- Current diagnosis of PCS.
- Current alcohol or drug abuse or dependence.
- Pregnancy.
- Under treatment for major illness or injury that may put the participant at higher
risk during participation (such as: IV therapy for severe infections, chemotherapy for
cancer, multiple necessary surgical interventions for injuries, unstable cardiac
disease, severe immune dysfunction, etc.).
- History of any endocrine disorder or dysfunction, unless cleared via an endocrinology
consult (including thyroid, adrenal and pituitary disorders).
- Abnormal lab values that may indicate endocrine disorder or dysfunction (unless
cleared by endocrine consult) or that may suggest major illness as described above as
determined by the screening clinician.
- Unstable diabetes.
Participant may be able to participate in the study but will not be able to have an MRI if
they have any of the following:
- Metal in the body such as pacemakers, stimulators, pumps, aneurysm clips, metallic
prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if
they are a welder or metal worker.
- Claustrophobia
- Are not able to lie comfortably flat on their back for up to 90 minutes.
Participant may be able to participate in the MRI but not the Affective Stroop portion of
the procedure if they are:
- Unable to see images close up without the aid of glasses (plastic goggles and contacts
are permissible)
- Are unable to use their index and pointer fingers on both hands for the task.
Participants may not participate in the hydrocortisone stimulation testing if they have any
of the following:
-History of any endocrine disorder or dysfunction, unless cleared via an endocrinology
consult (including thyroid, adrenal and pituitary
disorders)
- Abnormal lab values that may indicate endocrine disorder or dysfunction (unless
cleared by endocrine consult) or that may suggest major illness as described above as
determined by the screening clinician.
- Diabetes Mellitus
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 800-411-1222
Click here to add this to my saved trials
